A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin

Inclusion Criteria

• •Must have histologically confirmed squamous cell carcinoma or adenosquamous cell carcinoma of esophagus
• •Male or Female at least 18 years of age
• •Must have esophageal cancer that cannot be operated on, or treated with definitive chemoradiation with curative intent, that is advanced, reoccurring or has spread out
• •Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work
• •Must agree to provide tumor tissue sample, either from a previous surgery or biopsy within 6 months or fresh, prior to the start of treatment in this study